LAMTOR1

Across TCGA pan-cancer cohorts, LAMTOR1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LAMTOR1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LAMTOR1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LAMTOR1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and OV show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where LAMTOR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.554	0.925	.002	32	view →
LUAD	DFS	Median	III,IV	0.579	0.903	.009	18	view →
CCRCC	OS	Tertile	All	1.000	0.890	.013	14	view →
OV	DFS	Median	All	1.000	0.811	.009	4	view →
UCEC	DFS	Quartile	All	0.775	0.961	.031	4	view →
LSCC	OS	Median	All	1.000	0.934	.006	3	view →
HNSC	OS	Quartile	IV	0.485	0.955	.009	2	view →
GBM	OS	Median	All	0.784	0.929	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LAMTOR1–PDAC (OS)

Open the PDAC breakdown →